BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8778929)

  • 1. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
    Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
    Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
    Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
    Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
    Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
    Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
    Friess H; Langhans J; Ebert M; Beger HG; Stollfuss J; Reske SN; Büchler MW
    Gut; 1995 May; 36(5):771-7. PubMed ID: 7797130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can the extent of pancreatic tumors be evaluated reliably enough by positron emission tomography (PET)].
    Sendler A; Avril N; Roder JD; Schwaiger M; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1485-7. PubMed ID: 9931919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.
    Bares R; Klever P; Hellwig D; Hauptmann S; Fass J; Hambuechen U; Zopp L; Mueller B; Buell U; Schumpelick V
    Nucl Med Commun; 1993 Jul; 14(7):596-601. PubMed ID: 8355920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.